Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 10
Weighing CAR T Toxicity Profiles in Early R/R MM
Panelists discuss how recent data from the KarMMa-3 study influence the decision to treat early-stage relapsed/refractory multiple myeloma (R/R MM) with idecabtagene vicleucel (ide-cel), as well as the key toxicities considered when selecting chimeric antigen receptor (CAR) T-cell therapy. They also explore how these toxicities impact the transition of patients back to the community setting post CAR T and share strategies for managing early- and late-stage toxicities.
Video Player is loading.
Video content above is prompted by the following:
- Dr Rodriguez to Dr Neparidze: What toxicities do you weigh most when deciding which CAR T to use for early R/R MM?
- Dr Rodriguez to faculty: Post CAR T, how do those toxicities impact when you transition your patients back to the community setting?
- Dr Rodriguez to faculty: What strategies would you advise for managing and mitigating early- vs late-stage toxicities?
Related Content:
